Health
Why Regeneron Is Halting Coronavirus Antibody Cocktail Study Enrollment In Patients With Severe Cases – Benzinga
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 …
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 patients.
What Happened: An independent data monitoring committee recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold, citing a potential safety signal and an unfavorable risk-benefit profile at this time, Regeneron said Friday.
The committee recommended continuing the enrollment of hospitalized…
-
Noosa News19 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
Noosa News21 hours agoFuel tanker racing to unload in Darwin ahead of Tropical Cyclone Fina
-
Noosa News20 hours agoShattered families demand justice after Wieambilla killers not deemed terrorists
-
Noosa News23 hours ago50 years of SES in Noosa